Prostate cancer and microRNAs: New insights into apoptosis

Gupta, Jitendra; Abdulsahib, Waleed K.; Jalil, Abduladheem Turki; Kareem, Doaa Saadi; Aminov, Zafar; Alsaikhan, Fahad; Ramírez-Coronel, Ramirez-CoronelAndrés Alexis; Ramaiah, Pushpamala; Farhood, Bagher

doi:10.1016/j.prp.2023.154436

Cited by 6 publications

(6 citation statements)

References 318 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, specific target genes have been identified for miR-34a and miR-34c in cervical cancer. For instance, miR-34a has been reported to impede growth and migration by targeting CDC25A [116], a key cell cycle regulator. Similarly, miR-34c exerts suppressive effects on metastasis and invasion by targeting Notch 1 [49], a critical signaling pathway involved in cancer progression.…”

Section: The Role Of Mir-34s In Cervical Cancermentioning

confidence: 99%

MicroRNA-34 Family in Cancers: Role, Mechanism, and Therapeutic Potential

Fu,

Imani,

et al. 2023

Cancers

View full text Add to dashboard Cite

MicroRNA (miRNA) are small noncoding RNAs that play vital roles in post-transcriptional gene regulation by inhibiting mRNA translation or promoting mRNA degradation. The dysregulation of miRNA has been implicated in numerous human diseases, including cancers. miR-34 family members (miR-34s), including miR-34a, miR-34b, and miR-34c, have emerged as the most extensively studied tumor-suppressive miRNAs. In this comprehensive review, we aim to provide an overview of the major signaling pathways and gene networks regulated by miR-34s in various cancers and highlight the critical tumor suppressor role of miR-34s. Furthermore, we will discuss the potential of using miR-34 mimics as a novel therapeutic approach against cancer, while also addressing the challenges associated with their development and delivery. It is anticipated that gaining a deeper understanding of the functions and mechanisms of miR-34s in cancer will greatly contribute to the development of effective miR-34-based cancer therapeutics.

show abstract

Section: The Role Of Mir-34s In Cervical Cancermentioning

confidence: 99%

MicroRNA-34 Family in Cancers: Role, Mechanism, and Therapeutic Potential

Fu,

Imani,

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…The scientific literature indicates that miR-330 operates as a tumor suppressor in prostate cancer [ 55 , 56 ], and a high miR-330 expression can repress the propagation of colorectal cancer cells in vivo [ 57 ]. Nevertheless, the precise roles and underlying molecular mechanisms of miR-330 in the regulation of lung cancer remain enigmatic.…”

Section: Cell-free Mirnas As Diagnostic and Prognostic Biomarkersmentioning

confidence: 99%

Cell-Free miRNAs as Non-Invasive Biomarkers in Brain Tumors

Beylerli,

Encarnacion Ramirez,

Shumadalova

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Diagnosing brain tumors, especially malignant variants, such as glioblastoma, medulloblastoma, or brain metastasis, presents a considerable obstacle, while current treatment methods often yield unsatisfactory results. The monitoring of individuals with brain neoplasms becomes burdensome due to the intricate tumor nature and associated risks of tissue biopsies, compounded by the restricted accuracy and sensitivity of presently available non-invasive diagnostic techniques. The uncertainties surrounding diagnosis and the tumor’s reaction to treatment can lead to delays in critical determinations that profoundly influence the prognosis of the disease. Consequently, there exists a pressing necessity to formulate and validate dependable, minimally invasive biomarkers that can effectively diagnose and predict brain tumors. Cell-free microRNAs (miRNAs), which remain stable and detectable in human bodily fluids, such as blood and cerebrospinal fluid (CSF), have emerged as potential indicators for a range of ailments, brain tumors included. Numerous investigations have showcased the viability of profiling cell-free miRNA expression in both CSF and blood samples obtained from patients with brain tumors. Distinct miRNAs demonstrate varying expression patterns within CSF and blood. While cell-free microRNAs in the blood exhibit potential in diagnosing, prognosticating, and monitoring treatment across diverse tumor types, they fall short in effectively diagnosing brain tumors. Conversely, the cell-free miRNA profile within CSF demonstrates high potential in delivering precise and specific evaluations of brain tumors.

show abstract

“…Apoptosis is the most extensively studied form of regulated (programmed) cell death involving an energy-dependent cascade of molecular events [17][18][19]. There are two main pathways of apoptosis: the extrinsic (or death receptor) pathway and the intrinsic (or mitochondrial) pathway.…”

Section: Introductionmentioning

confidence: 99%

“…This interaction results in the activation of caspase 9, which in turn activates the executioner caspases (caspase 3 and caspase 7). The execution phase leading to cell demise has been recently referred to as "apoptosis" by the Nomenclature Committee on Cell Death [18] and others (e.g., [19]). This phase includes the externalization of phosphatidylserine (PS) on the outer plasma membrane leaflet, internucleosomal DNA cleavage, nuclear condensation, cell shrinkage, and the eventual formation of apoptotic bodies [17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

When Therapy-Induced Cancer Cell Apoptosis Fuels Tumor Relapse

Mirzayans

2024

Onco

View full text Add to dashboard Cite

Most therapeutic strategies for solid tumor malignancies are designed based on the hypothesis that cancer cells evade apoptosis to exhibit therapy resistance. This is somewhat surprising given that clinical studies published since the 1990s have demonstrated that increased apoptosis in solid tumors is associated with cancer aggressiveness and poor clinical outcome. This is consistent with more recent reports demonstrating non-canonical (pro-survival) roles for apoptotic caspases, including caspase 3, as well as the ability of cancer cells to recover from late stages of apoptosis via a process called anastasis. These activities are essential for the normal development and maintenance of a healthy organism, but they also enable malignant cells (including cancer stem cells) to resist anticancer treatment and potentially contribute to clinical dormancy (minimal residual disease). Like apoptosis, therapy-induced cancer cell dormancy (durable proliferation arrest reflecting various manifestations of genome chaos) is also not obligatorily a permanent cell fate. However, as briefly discussed herein, compelling pre-clinical studies suggest that (reversible) dormancy might be the “lesser evil” compared to treacherous apoptosis.

show abstract

Prostate cancer and microRNAs: New insights into apoptosis

Cited by 6 publications

References 318 publications

MicroRNA-34 Family in Cancers: Role, Mechanism, and Therapeutic Potential

MicroRNA-34 Family in Cancers: Role, Mechanism, and Therapeutic Potential

Cell-Free miRNAs as Non-Invasive Biomarkers in Brain Tumors

When Therapy-Induced Cancer Cell Apoptosis Fuels Tumor Relapse

Contact Info

Product

Resources

About